- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Novartis acquires pharmaceutical company
Author(s):
Swiss drugmaker Novartis has signed an agreement to acquire Fougera Pharmaceuticals for more than $1.5 billion in cash.
Basel, Switzerland - Swiss drugmaker Novartis has signed an agreement to acquire Fougera Pharmaceuticals for more than $1.5 billion in cash.
The purchase of Fougera, a specialty dermatology generics company headquartered in Melville, N.Y., is expected to be another boost for Sandoz, the division of Novartis specializing in generic drugs, Reuters reports. According to 2011 data from consulting firm IMS, the move will make Sandoz the top seller of generic dermatology medication.
Fougera Pharmaceuticals operates two main divisions: Fougera, a leading player in the $2.1 billion U.S. dermatology generics sector with 45 products, and PharmaDerm, a specialty pharma business with 17 brands.
According to Reuters, the transaction will require regulatory approvals and is expected to be complete before January 2013.
Go back to the Dermatology Times eNews newsletter.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
